Present and potential future paradigms for the treatment of ST-segment elevation acute myocardial infarction

Journal of Invasive Cardiology

Volumn 14, Issue SUPPL. A, 2002, Pages

  Chew, Derek P ^a   Moliterno, David J ^a   Herrmann, Howard C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; CELL ADHESION MOLECULE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; LANOTEPLASE; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RETEPLASE; STREPTOKINASE; TENECTEPLASE; TIROFIBAN; VITRONECTIN RECEPTOR;

ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; CORONARY STENT; DOSE RESPONSE; DRUG BINDING; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEART CATHETERIZATION; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REPERFUSION; HUMAN; META ANALYSIS; REVIEW; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TREATMENT OUTCOME;

EID: 0036174066     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: The Rapid Early Action for Coronary Treatment (REACT) trial
2. Facilitated percutaneous coronary intervention: Validating the open artery hypothesis
3. Treatment of unstable angina: The role of platelet inhibitors and anticoagulants
4. Heparin
5. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
6. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction
7. A comparison of reteplase with alteplase for acute myocardial infarction. The global use of strategies to open occluded coronary arteries
8. Single-bolus tenecteplase compared with frontloaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial
9. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
10. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
11. A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction: ISIS-3
12. Angiographically assessed coronary arterial patency and reocclusion in patients with acute myocardial infarction treated with anistreplase: Results of the anistreplase reocclusion multicenter study (ARMS)
13. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: Results of the rt-PA-APSAC patency study (TAPS)
14. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
15. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings
16. The GISSI-2 trial: Premises, results, epidemiological (and other) implications
17. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase (r-PA) compared with alteplase infusion in acute myocardial infarction
18. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction
19. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial
20. Evaluation of a weight-adjusted singlebolus plasminogen activator in patients with myocardial infarction: A double-blind, randomized angiographic trial of lanoteplase versus alteplase
21. Intravenous NPA for the treatment of infarcting myocardium early. InTIME-II, a double-blind comparison of single-bolus lanoteplase vs. accelerated alteplase for the treatment of patients with acute myocardial infarction
22. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial
23. Safety assessment of single-bolus administration of TNK tissue plasminogen activator in acute myocardial infarction: The ASSENT-I trial
24. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction
25. The role of thrombolytic drugs in the management of myocardial infarction: Comparative clinical trials
26. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion
27. Thrombolysis medication errors: Benefits of bolus thrombolytic agents
28. Time to treatment and cost of thrombolysis: A multicenter comparison of tPA and rPA
29. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
30. The ideal fibrinolytic: Can drug design improve clinical results?
31. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?
32. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence
33. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The global use of strategies to open occluded coronary arteries
34. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial
35. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
36. Lower dose heparin with thrombolysis is associated with lower rates of intracranial hemorrhage: Results from TIMI 10B and ASSENT 1
37. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction
38. The relevance of platelet and fibrin thromboembolism of the coronary microcirculation, with special reference to sudden cardiac death
39. Primary stenting in acute myocardial infarction: The promise and the proof
40. Effectiveness of early coronary angioplasty and abciximab for failed fibrinolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial)
41. Ischemic complications after percutaneous transluminal coronary angioplasty
42. Triple therapy for acute myocardial infarction: Combining fibrinolysis, platelet IIb/IIIa inhibition, and percutaneous coronary intervention
43. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction
44. Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? Thrombolysis - The preferred treatment
45. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4 Pilot) trial
46. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
47. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction
48. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction. Analysis from the primary angioplasty in myocardial infarction trials
49. Combination reperfusion therapy with abciximab and reduced dose reteplase: Results from TIMI-14
50. Primary angioplasty compared with thrombolysis: New issues in the era of glycoprotein IIb/IIIa inhibition and coronary stenting
51. Coronary angioplasty with or without stent implantation for acute myocardial infarction
52. Platelet glycoprotein IIb/IIIa integrin inhibition in acute myocardial infarction
53. Glycoprotein IIb/IIIa receptor antagonists in percutaneous coronary intervention
54. Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use?
55. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment
56. Randomized, doubleblind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty
57. Pathology of acute and chronic coronary stenting in humans
58. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
59. TARGET 6-month results: Tirofiban catching up
60. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
61. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The ESPRIT trial: A randomized controlled trial
62. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction
63. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus thrombolysis for occluded coronary arteries in patients with Acute Myocardial Infarction Study Investigators
64. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study
65. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, doseranging trial
66. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial
67. Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction
68. Randomized, placebocontrolled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
69. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction
70. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction
71. Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes
72. Dawning of a new era in cardiovascular medicine: Applying evidence-based medicine to real-life practice
73. Potential non-glycoprotein IIb/IIIa effects of abciximab
74. Effects of platelet glycoprotein IIb/IIIa receptor blockade by chimeric monoclonal antibody (abciximab) on acute and six month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction
75. Effect of glycoprotein IIb/IIIa inhibition without fibrinolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot study
76. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis In Myocardial Infarction (TIMI)-14 trial